Steven Leonard Chapman Sells 83,223 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRAGet Free Report) CEO Steven Leonard Chapman sold 83,223 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $88.96, for a total value of $7,403,518.08. Following the sale, the chief executive officer now owns 232,004 shares of the company’s stock, valued at $20,639,075.84. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

  • On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total value of $824,045.36.
  • On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The stock was sold at an average price of $65.09, for a total value of $964,178.17.
  • On Monday, January 22nd, Steven Leonard Chapman sold 1,958 shares of Natera stock. The stock was sold at an average price of $68.16, for a total value of $133,457.28.
  • On Thursday, December 28th, Steven Leonard Chapman sold 2,604 shares of Natera stock. The stock was sold at an average price of $63.29, for a total value of $164,807.16.

Natera Stock Performance

Shares of NASDAQ:NTRA traded up $1.81 during trading on Friday, hitting $89.52. 2,077,676 shares of the stock were exchanged, compared to its average volume of 1,507,271. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $93.48. The company has a market capitalization of $10.81 billion, a price-to-earnings ratio of -23.62 and a beta of 1.39. The company’s fifty day simple moving average is $73.08 and its 200-day simple moving average is $58.94. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. TD Cowen raised their price target on Natera from $82.00 to $87.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. BTIG Research raised their price target on Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. Canaccord Genuity Group raised their price target on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Stephens reissued an “overweight” rating and issued a $78.00 price objective on shares of Natera in a research note on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $78.36.

Read Our Latest Stock Report on NTRA

Institutional Trading of Natera

Institutional investors have recently modified their holdings of the company. RiverPark Advisors LLC acquired a new stake in shares of Natera during the 4th quarter worth approximately $27,000. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in Natera in the 2nd quarter valued at $29,000. Principal Securities Inc. acquired a new stake in Natera in the 4th quarter valued at $32,000. Pinebridge Investments L.P. acquired a new stake in Natera in the 2nd quarter valued at $33,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Natera in the 3rd quarter valued at $44,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Read More

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.